Emily M. Leproust Sells 5,139 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 5,139 shares of the stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $205,200.27. Following the transaction, the chief executive officer now owns 499,593 shares in the company, valued at approximately $19,948,748.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock traded down $1.64 during trading hours on Wednesday, hitting $44.60. The company’s stock had a trading volume of 1,109,494 shares, compared to its average volume of 1,052,113. Twist Bioscience Co. has a 12-month low of $14.42 and a 12-month high of $60.90. The business has a 50 day moving average price of $50.72 and a two-hundred day moving average price of $41.58. The company has a market cap of $2.60 billion, a PE ratio of -13.97 and a beta of 1.80.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The company had revenue of $81.50 million for the quarter, compared to analysts’ expectations of $77.40 million. During the same period last year, the business earned ($1.01) earnings per share. The company’s quarterly revenue was up 27.7% compared to the same quarter last year. As a group, research analysts anticipate that Twist Bioscience Co. will post -3.08 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Barclays lowered their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday. Scotiabank raised their target price on Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research report on Monday, May 6th. Guggenheim started coverage on shares of Twist Bioscience in a research report on Tuesday, June 4th. They set a “buy” rating and a $53.00 price target for the company. TD Cowen raised their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Finally, Robert W. Baird upped their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday. One investment analyst has rated the stock with a sell rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $48.22.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. International Assets Investment Management LLC grew its stake in Twist Bioscience by 3,519.8% in the 4th quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock worth $148,000 after acquiring an additional 3,907 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in Twist Bioscience by 2.9% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,583,443 shares of the company’s stock worth $132,086,000 after purchasing an additional 99,511 shares during the period. Knights of Columbus Asset Advisors LLC bought a new stake in Twist Bioscience during the 4th quarter valued at $2,296,000. New York State Common Retirement Fund lifted its holdings in shares of Twist Bioscience by 5.0% in the 4th quarter. New York State Common Retirement Fund now owns 370,849 shares of the company’s stock worth $13,669,000 after buying an additional 17,715 shares during the period. Finally, Victory Capital Management Inc. bought a new position in shares of Twist Bioscience during the 4th quarter worth $274,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.